Profile data is unavailable for this security.
About the company
Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company's digestive health and other product offerings also include skin health and smoker’s health. Its oral health brands include Sensodyne, Polident, Parodontax, and Biotene. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, and Flonase. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Fenistil.
- Revenue in GBP (TTM)11.23bn
- Net income in GBP1.44bn
- Incorporated2021
- Employees24.00k
- LocationHaleon PLCBuilding 5, First Floor, The HeightsWEYBRIDGE KT13 0NYUnited KingdomGBR
- Phone+44 193 282 2000
- Websitehttps://www.haleon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | 39.80bn | -2.78bn | 22.65bn | 90.89k | -- | 0.8167 | 4.73 | 0.569 | -3.31 | -3.31 | 47.41 | 33.03 | 0.4067 | 1.64 | 3.39 | 501,847.80 | -2.83 | -2.66 | -3.81 | -3.61 | 53.99 | 57.98 | -6.96 | -6.88 | 0.792 | 2.54 | 0.5473 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| UCB SA | 5.26bn | 910.05m | 28.29bn | 9.38k | 31.05 | 3.23 | 20.06 | 5.38 | 5.48 | 5.48 | 31.62 | 52.77 | 0.3741 | 1.50 | 4.48 | 656,003.40 | 6.48 | 4.98 | 7.97 | 6.20 | 71.52 | 71.71 | 17.31 | 13.00 | 0.9858 | 8.91 | 0.2319 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Alnylam Pharmaceuticals, Inc. | 1.71bn | -196.64m | 30.69bn | 2.23k | -- | 364.43 | -- | 17.93 | -2.09 | -2.09 | 18.27 | 0.8858 | 0.5842 | 4.12 | 9.70 | 1,052,959.00 | -6.71 | -20.07 | -8.96 | -25.51 | 86.01 | 84.18 | -11.49 | -55.19 | 2.98 | -0.4627 | 0.8988 | -- | 22.97 | 59.21 | 36.82 | -- | -24.55 | -- |
| Daiichi Sankyo Co Ltd | 9.51bn | 1.49bn | 31.48bn | 19.77k | 21.15 | 3.79 | 17.15 | 3.31 | 155.87 | 155.87 | 994.10 | 869.69 | 0.5454 | 0.8726 | 4.24 | 95,434,150.00 | 8.55 | 5.72 | 10.87 | 7.11 | 77.96 | 72.15 | 15.68 | 11.03 | 1.85 | -- | 0.0876 | 49.57 | 17.77 | 13.95 | 44.47 | 17.77 | 29.01 | 20.79 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 2.97bn | 695.46m | 33.69bn | 20.24k | 48.11 | 7.05 | -- | 11.35 | 1.08 | 1.08 | 4.61 | 7.37 | 0.598 | 1.81 | 6.05 | 1,442,469.00 | 14.02 | 12.67 | 15.31 | 14.00 | 85.50 | 85.64 | 23.45 | 20.06 | 9.98 | -- | 0.0023 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Haleon PLC | 11.23bn | 1.44bn | 33.99bn | 24.00k | 24.09 | 2.12 | -- | 3.03 | 0.1571 | 0.1571 | 1.22 | 1.79 | 0.3286 | 3.39 | 5.49 | 468,041.70 | 4.31 | 3.67 | 5.11 | 4.23 | 60.75 | 62.28 | 13.13 | 11.97 | 0.7791 | 8.48 | 0.3843 | 218.65 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| Sun Pharmaceutical Industries Ltd | 4.49bn | 964.67m | 34.55bn | 43.00k | 35.77 | 5.61 | 29.06 | 7.70 | 47.18 | 45.60 | 219.42 | 300.99 | 0.5922 | 1.07 | 4.33 | -- | 12.79 | 9.19 | 16.38 | 12.51 | 79.56 | 74.04 | 21.60 | 16.24 | 2.33 | 272.98 | 0.0316 | 39.50 | 8.42 | 9.87 | 18.07 | 24.60 | 6.66 | 31.95 |
| Takeda Pharmaceutical Co Ltd | 23.09bn | 543.95m | 35.01bn | 47.46k | 65.33 | 0.9907 | 7.99 | 1.52 | 66.83 | 66.83 | 2,880.43 | 4,407.01 | 0.3121 | 1.30 | 7.25 | 96,545,170.00 | 0.7367 | 1.71 | 0.8815 | 2.04 | 65.51 | 67.66 | 2.36 | 5.99 | 0.5202 | 2.52 | 0.3943 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| Merck KGaA | 18.21bn | 2.41bn | 41.85bn | 62.60k | 17.37 | 1.64 | 10.30 | 2.30 | 6.48 | 6.48 | 49.08 | 68.59 | 0.4312 | 1.88 | 4.89 | 340,745.30 | 5.71 | 6.04 | 7.12 | 7.70 | 59.21 | 61.15 | 13.24 | 13.80 | 0.8313 | 32.43 | 0.2252 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Mar 2025 | 559.94m | 6.18% |
| The Vanguard Group, Inc.as of 01 May 2025 | 290.44m | 3.21% |
| Dodge & Coxas of 30 Sep 2024 | 233.28m | 2.58% |
| BlackRock Fund Advisorsas of 06 Mar 2025 | 196.79m | 2.17% |
| BlackRock Investment Management (UK) Ltd.as of 01 May 2025 | 176.04m | 1.94% |
| Norges Bank Investment Managementas of 01 May 2025 | 170.84m | 1.89% |
| MFS International (UK) Ltd.as of 01 May 2025 | 154.58m | 1.71% |
| Franklin Mutual Advisers LLCas of 01 May 2025 | 136.44m | 1.51% |
| First Eagle Investment Management LLCas of 01 May 2025 | 134.37m | 1.48% |
| Harding Loevner LPas of 01 May 2025 | 132.71m | 1.47% |
